In contrast, in our study, most of the examined lipid metabolism-related genes, such as VLDL-R, SR-A, SR-B1, CD36, and ABCG1, were unaffected by either NA/STZ-induced hyperglycemia or treatment with luseogliflozin, although the reduction in LDL-R and the increase in ABCA1 mRNAs were exceptions, observed with seven days of luseogliflozin treatment. The gene discussed is CD36; the disease is Hyperglycemia.